The present invention is directed to a vaccine comprising recombinant antigens derived from the parasitic nematode Haemonchus contortus, which will raise an immune response in farmed and wild ruminants that are susceptible or predisposed to infection by one or more nematode worm species. The recombinant antigens used in the invention are conserved among species of nematode worms so that the vaccine will provide protection against multiple types of nematode worms. In particular, the invention provides a composition or vaccine composition comprising the recombinant H. contortus antigens: (i) enolase (EN); (ii) arginine kinase (AK); and (iii) ornithine decarboxylase (ODC), or antigenic fragments thereof, together with a veterinary acceptable carrier or diluent.

Provided herein are methods for treating an angiogenesis-related disease comprising administration to a subject in need thereof an effective amount of alpha-enolase (enolase-1. ENO-1) antagonist.

The present invention relates to the field of fungal biotechnology, more particularly to genetic engineering methods for the production of polyunsaturated fatty acids (PUFA) in fungal hosts selected from Rhodosporidium and Rhodotorula genera. The present invention further relates to a modified fungal host cell having reduced native aldehyde dehydrogenase (ALD 1) enzyme activity, and methods for producing omega-3 and omega-6 fatty acids and triacylglycerides, by growing said fungal host cell under suitable conditions.

A microorganism which is genetically modified so that it produces a first essential biomass precursor by metabolizing CO.sub.2 using a recombinant carbon fixation enzyme is disclosed. The microorganism produces a second biomass precursor by metabolizing an organic carbon source and not by metabolizing CO.sub.2. The microorganism does not use the organic carbon source for producing the first essential biomass precursor.

The present disclosure relates, in some aspects, to cell-free methods and systems for large-scale conversion of methane to isobutanol, comprising combining, in a bioreactor at elevated pressure, methane, oxygen, and cell lysates containing methane monooxygenase, methanol dehydrogenase, and enzymes that catalyze the conversion of formaldehyde to isobutanol, to form a cell-free reaction mixture, and incubating under suitable conditions the cell-free reaction to convert methane to isobutanol.

The present disclosure relates, in some aspects, to cell-free methods and systems for large-scale conversion of methane to isobutanol, comprising combining, in a bioreactor at elevated pressure, methane, oxygen, and cell lysates containing methane monooxygenase, methanol dehydrogenase, and enzymes that catalyze the conversion of formaldehyde to isobutanol, to form a cell-free reaction mixture, and incubating under suitable conditions the cell-free reaction to convert methane to isobutanol.

The present invention relates to methods for constructing a recombinant fungal host cell comprising one or more copies of a polynucleotide construct integrated in its genome, said method comprising transforming a fungal host cell with an integrative polynucleotide construct comprising a first polynucleotide encoding a selectable marker, wherein the first polynucleotide, a 5 untranslated region thereof and/or a riboswitch operably linked therewith comprises a spliceosomal intron which has 5 nucleotides or less between its branch site and its acceptor site; and a second polynucleotide encoding a polypeptide of interest; as well as suitable polynucleotide constructs, resulting fungal host cells and methods of manufacture.

The invention provides compositions comprising Eno1 and a muscle targeting peptide, e.g, as a fusion protein, for delivery of Eno1 to a muscle. The Eno1 may contain one or more added cysteine residues which are covalently attached to a biocompatible polymer (e.g. polyethylene glycol). Further, the invention provides a method for normalizing blood glucose in a subject with elevated blood glucose, comprising administering to the subject enolase 1 (Eno1), thereby normalizing blood glucose in the subject. The invention also provides methods of treating one or more conditions including impaired glucose tolerance, insulin resistance, pre-diabetes, and diabetes, especially type 2 diabetes in a subject, comprising administering to the subject enolase 1 (Eno1), thereby treating the condition in the subject.

Provided is a promoter having high foreign gene expression-enhancing activity in host cells such as cultured mammalian cells. An approach for using the promoter to enhance the production of a foreign protein to be used as a protein-based pharmaceutical product is the provision of a polynucleotide that is a Chinese hamster-derived gene promoter, the polynucleotide comprising a nucleotide sequence that is selected from SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13 and SEQ ID NO: 14, or has 85% or higher sequence identity to each of the sequences, or a partial sequence of the nucleotide sequence.

The present invention relates to epitopes containing homocitrulline (Heit) that can be used as targets for cancer immunotherapy. The homocitrullinated T cell epitope has (i) a predicted binding score to MIC class II or class I of <30 using the online IEDB prediction program (http://www.iedb.org/) and (ii) at least 5 consecutive amino acids that form a spiral conformational structure. These modified peptides can be used as vaccines or as targets for T cell receptor (TCR) and adoptive T cell transfer therapies.